biostudies-literatureUnknown7(4)Palazzolo JSThrombolysis with tissue-type plasminogen activator (tPA) remains the main treatment for acute ischemic stroke. Nevertheless, tPA intervention is limited by a short therapeutic window, low recanalization rates, and a risk of intracranial hemorrhage (ICH), highlighting the clinical demand for improved thrombolytic drugs. We examined a novel thrombolytic agent termed "SCE5-scuPA," comprising a single-chain urokinase plasminogen activator (scuPA) fused with a single-chain antibody (SCE5) that targets the activated glycoprotein IIb/IIIa platelet receptor, for its effects in experimental stroke. SCE5-scuPA was first tested in a whole blood clot degradation assay to show the benefit of platelet-targeted thrombolysis. The tail bleeding time, blood clearance, and biodistribution were then determinBlood advances561-574https://www.ebi.ac.uk/biostudies/studies/S-EPMC9984306biostudies-literaturePlatelet-targeted thrombolysis for treatment of acute ischemic stroke.PMC9984306Alt KJagdale SBroughton BRSWright DKHagemeyer CEPalazzolo JSNiego BMedcalf RLAle AHo HfalsePlatelet-targeted thrombolysis for treatment of acute ischemic stroke.Thrombolysis with tissue-type plasminogen activator (tPA) remains the main treatment for acute ischemic stroke. Nevertheless, tPA intervention is limited by a short therapeutic window, low recanalization rates, and a risk of intracranial hemorrhage (ICH), highlighting the clinical demand for improved thrombolytic drugs. We examined a novel thrombolytic agent termed "SCE5-scuPA," comprising a single-chain urokinase plasminogen activator (scuPA) fused with a single-chain antibody (SCE5) that targets the activated glycoprotein IIb/IIIa platelet receptor, for its effects in experimental stroke. SCE5-scuPA was first tested in a whole blood clot degradation assay to show the benefit of platelet-targeted thrombolysis. The tail bleeding time, blood clearance, and biodistribution were then determin2023-01-01T00:00:00Z2023 Feb2025-05-29T16:30:27.09Z2025-04-06T12:22:43.212ZS-EPMC99843063548290910.1182/bloodadvances.2021006691